These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 1426303

  • 1. The prognostic value of the tumour markers CA 195 and CEA in patients with adenocarcinoma of the pancreas.
    Taylor OM, Cooper EH, Benson EA, McMahon MJ.
    Eur J Surg Oncol; 1992 Oct; 18(5):508-13. PubMed ID: 1426303
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R, Billi P, Plate L, Laudadio MA, Sprovieri G.
    Ital J Gastroenterol; 1995 Oct; 27(6):296-9. PubMed ID: 8562994
    [Abstract] [Full Text] [Related]

  • 4. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R.
    Anticancer Res; 2000 Oct; 20(6D):5195-8. PubMed ID: 11326694
    [Abstract] [Full Text] [Related]

  • 5. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1992 Oct; 12(5):1687-93. PubMed ID: 1332581
    [Abstract] [Full Text] [Related]

  • 6. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F, Kantor J, Aloe S, Carone MD, Spila A, D'Alessandro R, Abbolito MR, Cosimelli M, Graziano F, Carboni F, Carlini S, Perri P, Sciarretta F, Greiner JW, Kashmiri SV, Steinberg SM, Roselli M, Schlom J.
    Cancer Res; 2001 Mar 15; 61(6):2523-32. PubMed ID: 11289125
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.
    Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, Fateh-Moghadam A.
    Anticancer Res; 1997 Mar 15; 17(4B):2903-6. PubMed ID: 9329559
    [Abstract] [Full Text] [Related]

  • 9. CEA and CA 19-9 as prognostic indexes in colorectal cancer.
    Forones NM, Tanaka M.
    Hepatogastroenterology; 1999 Mar 15; 46(26):905-8. PubMed ID: 10370636
    [Abstract] [Full Text] [Related]

  • 10. [A clinical study on CA 15-3, CEA, SCC-Ag in patients with squamous cell carcinoma of the lung].
    Moriya H, Suzuki S, Aizumi J, Kimura K, Urabe S, Higuci Y, Hoshi K.
    Rinsho Hoshasen; 1989 Jan 15; 34(1):63-6. PubMed ID: 2724610
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Tumor markers in the upper intestinal tract--stomach and pancreas].
    Pointner R, Conrad F, Schwab G.
    Wien Klin Wochenschr; 1989 Jul 14; 101(14):482-4. PubMed ID: 2773485
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA, Behbehani AE, el-Nass SA, Temim L, Ebraheem AK, Ali MA, Szymendera JJ.
    Eur J Surg Oncol; 1993 Feb 14; 19(1):74-9. PubMed ID: 8436243
    [Abstract] [Full Text] [Related]

  • 15. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
    Safi F, Roscher R, Beger HG.
    Hepatogastroenterology; 1989 Dec 14; 36(6):419-23. PubMed ID: 2613165
    [Abstract] [Full Text] [Related]

  • 16. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
    Duk JM, Aalders JG, Fleuren GJ, Krans M, De Bruijn HW.
    Obstet Gynecol; 1989 Apr 14; 73(4):661-8. PubMed ID: 2648225
    [Abstract] [Full Text] [Related]

  • 17. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1995 Apr 14; 15(6B):2731-7. PubMed ID: 8669855
    [Abstract] [Full Text] [Related]

  • 18. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
    Lucarotti ME, Habib NA, Kelly SB, Rothnie ND, Nelson O, Lindholm L, Cooper MJ, Wood CB, Williamson RC.
    Eur J Surg Oncol; 1991 Feb 14; 17(1):51-3. PubMed ID: 1995358
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K.
    J Hepatobiliary Pancreat Surg; 2007 Feb 14; 14(6):539-44. PubMed ID: 18040617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.